ERBB2 was amplified in 5.2 % (27/523) of tumors in the cohort, and in the subset of ERBB2 amplified tumors, 92.6 % (25/26) were found in CNH endometrial cancer. This evidence concerns the gene ERBB2 and endometrial cancer.